EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative efficacy and safety of mesalazine-based regimens with traditional Chinese medicines in mild-to-moderate ulcerative colitis

Bin Huang, Honglin An, Liming Chen, Huimin Lin, Huaping Wu, Ruofei Li, Yaping Su, Jiumao Lin, Dan Shi

Frontiers in Pharmacology · 13.01.2026 · 16

DOI: 10.3389/fphar.2025.1691460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.01.2026. Verfasst von Bin Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatrics, Key laboratory of Integrative Medicine of Fujian Provin…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Traditional Chinese medicine (TCM) formulations are increasingly used in combination with mesalazine to treat mild-to-moderate active ulcerative colitis (UC). However, direct comparisons between various TCM regimens are limited.

Methods

We performed a frequentist network meta-analysis of 34 randomized controlled trials (n = 2,854) comparing oral mesalazine (1.0–4.0 g/day) alone versus mesalazine plus one of eight TCM formulations: Kangfuxin solution, Shaoyao decoction, Glycyrrhizae decoction, Scutellaria decoction (Huangqin granules), Baitouweng decoction (Pulsatilla; retention enema), Shenling Baizhu Powder, CurQD formula, or Fufangkushen capsules. Outcomes included clinical efficacy, adverse events, Mayo score, serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and intestinal Bifidobacteria, Lactobacilli, and Escherichia coli . Risk ratios (RRs) were calculated for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Treatments were ranked using surface under the cumulative ranking curve (SUCRA).

Results

Most TCM–mesalazine combinations improved clinical efficacy versus mesalazine alone. CurQD and Kangfuxin had the highest probabilities of being most effective for symptom improvement (SUCRA 96.7% and 72.7%, respectively); the direct CurQD–mesalazine comparison showed RR = 2.67 (95% CI 1.16–6.14). Adverse-event rates were similar across regimens, with lower incidence of adverse events. Mayo score reductions were greatest with Glycyrrhizae decoction (MD = −1.40), Baitouweng decoction via retention enema (MD = −1.09), and Kangfuxin solution (MD = −1.07). Scutellaria granules produced the largest IL-6 decrease (MD = −53.28 pg/mL) and ranked highest for TNF-α reduction, followed by Kangfuxin. For gut microbiota, Shaoyao decoction ranked highest for increasing Bifidobacteria, Glycyrrhizae decoction for increasing Lactobacilli, and Glycyrrhizae also reduced E. coli (MD = −1.93).

Conclusion

Combining mesalazine with selected TCM formulations can enhance clinical response, reduce inflammatory cytokines, and beneficially modulate gut microbiota without increasing adverse events. CurQD or Kangfuxin may be prioritized for symptomatic improvement, Glycyrrhizae or Baitouweng for Mayo score reduction, Scutellaria for cytokine control, and Shaoyao or Glycyrrhizae for microbiota modulation. High-quality multicenter RCTs are warranted to confirm these comparative rankings.

Schlagwörter

Stichwörter der Autor:innen

TNF-αmesalazinenetwork meta-analysistraditional Chinese medicineulcerative colitis

Autor:innen und Institutionen

  • Academy of Integrative Medicine, Fujian Key Laboratory of Integrative Medicine on Geriatrics, Key laboratory of Integrative Medicine of Fujian Province University, Fujian University of Traditional Chinese Medicine, Fuzh…
  • The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
  • The Third People's Hospital of Fujian Province, Fuzhou, Fujian, China.
  • Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, China.

Zitieren

APA

Huang, B., An, H., Chen, L., Lin, H., Wu, H., Li, R., Su, Y., Lin, J., & Shi, D. (2026). Comparative efficacy and safety of mesalazine-based regimens with traditional Chinese medicines in mild-to-moderate ulcerative colitis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1691460

Vancouver

Huang B, An H, Chen L, Lin H, Wu H, Li R, et al. Comparative efficacy and safety of mesalazine-based regimens with traditional Chinese medicines in mild-to-moderate ulcerative colitis. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1691460

BibTeX
@article{Huang2026,
  author = {Huang, Bin and An, Honglin and Chen, Liming and Lin, Huimin and Wu, Huaping and Li, Ruofei and Su, Yaping and Lin, Jiumao and Shi, Dan},
  title = {Comparative efficacy and safety of mesalazine-based regimens with traditional Chinese medicines in mild-to-moderate ulcerative colitis},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fphar.2025.1691460}
}
Kostenlos starten →